HRP20201422T1 - Ljudska anti-tau antitijela - Google Patents
Ljudska anti-tau antitijela Download PDFInfo
- Publication number
- HRP20201422T1 HRP20201422T1 HRP20201422TT HRP20201422T HRP20201422T1 HR P20201422 T1 HRP20201422 T1 HR P20201422T1 HR P20201422T T HRP20201422T T HR P20201422TT HR P20201422 T HRP20201422 T HR P20201422T HR P20201422 T1 HRP20201422 T1 HR P20201422T1
- Authority
- HR
- Croatia
- Prior art keywords
- tau
- binding fragment
- antibody
- disease
- seq
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 208000034799 Tauopathies Diseases 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000000626 neurodegenerative effect Effects 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Claims (12)
1. Monoklonsko anti-tau antitijelo ili njegov tau-vezujući fragment, naznačeno time što:
(a) varijabilna regija teškog lanca (VH) sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 48 i
varijabilna regija lakog lanca (VL) sadrži aminokiselinsku sekvencu naveden u SEQ ID NO: 49, ili
(b) VH sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 47, a VL sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 49.
2. Anti-tau antitijelo ili njegov tau-vezujući fragment prema zahtjevu 1, naznačeno time što je anti-tau antitijelo ili tau-vezujući fragment odabran iz skupine koja sadrži Fab, Fab', F (ab')2, i Fd, i Fv, jednolančani Fv (scFv), i jednolančano antitijelo i Fv (sdFv).
3. Anti-tau antitijelo ili njegov tau-vezujući fragment prema zahtjevu 1 ili 2, naznačeno time što anti-tau antitijelo ili njegov tau-vežući fragment sadrži polietilen glikol ili detektirajuću etiketu odabranu iz skupine koja se sastoji od enzima, radioizotopa, fluorescentnog spoja, kemiluminiscentnog spoja, bioluminescentnog spoja i teškog metala.
4. Farmaceutski pripravak koji sadrži anti-tau antitijelo ili njegov tau-vežući fragment prema bilo kojem od zahtjeva 1-3, i farmaceutski prihvatljiv nosač.
5. Izolirani polinukleotid ili polinukleotidi koji sadrže nukleotidnu sekvencu ili nukleotidne sekvence koji kodiraju anti-tau antitijelo ili njegov tau-vezujući fragment prema zahtjevu 1 ili 2.
6. Polinukleotid ili polinukleotidi prema zahtjevu 5, naznačeni time što sadrže niz sekvenca nukleinskih kiselina naveden u SEQ ID NO: 173 i SEQ ID NO: 174.
7. Ekspresijski vektor ili vektori koji sadrže polinukleotid ili polinukleotide prema zahtjevu 5 ili 6.
8. Izolirana stanica domaćina koja sadrži ekspresijski vektor ili vektore prema zahtjevu 7 ili polinukleotid ili polinukleotide prema zahtjevu 5 ili 6.
9. Postupak za pripremu anti-tau antitijela ili njegovog tau-vezujućeg fragmenta, postupak sadrži:
uzgoj stanice domaćina prema zahtjevu 8 u staničnoj kulturi, i
izoliranje anti-tau antitijela ili njegovog tau-vezujućeg fragmenta iz stanične kulture.
10. Anti-tau antitijelo ili tau-vežući fragment prema bilo kojim od zahtjeva 1-3 ili farmaceutski pripravak prema zahtjevu 4, naznačen time što se upotrebljava u liječenju neurodegenerativne taupatije kod ljudskog subjekta kojem je to potrebno, poželjno gdje je neurodegenerativna taupatija odabrana iz skupine koji se sastoji od Alzheimerove bolesti, kompleksa amiotrofične lateralne skleroze / parldonizam-demencije, demencije argirofilnih zrnaca, amiloidne angiopatije britanskog tipa, cerebralne amiloidne angiopatije, kortikobazalne degeneracije, bolesti Creutzfeldta-Jakoba, pugilističke demencije, difuzne neurofibrilarne zapetljanosti s kalcifikacijom, Downovog sindroma, frontotemporalne demencije, frontotemporalne demencije parkinsonizma povezanog sa kromosomom 17, frontotemporalne lobarne degeneracije, GerstmannStréiussler-Scheinker bolesti, Hallervorden-Spatz bolesti, inkluzijskog miozitisa tijela, atrofije više sustava, miotonske distrofije, Niemann-Pickove bolesti tipa C, ne-gvamske bolesti motornog neurona s neurofibrilarnim zapetljanjima, Pickove bolesti, postencefalitičkog parkinsonizama, prethodne proteinske cerebralne amiloidne angiopatije, progresivne subkortikalne glioze, progresivne supranuklearne paralize, subkutanog sklerozirajućeg panencefalitisa, demencije samo sa zapetljanjima, demencije multi-infarkta i ishemičnog moždanog udara.
11. Anti-tau antitijelo ili tau-vežući fragment prema bilo kojem od zahtjeva 1-3 za uporabu u in vivo dijagnostici tauopatije kod ljudskog pacijenta kojem je to potrebno.
12. In vitro metoda dijagnosticiranja ili praćenja progresije neurodegenerativne taupatije, postupak sadrži:
(a) mjerenje razine patološki modificiranog ili agregiranog tau-a u uzorku dobivenom od ljudskog subjekta s anti-tau antitijelom ili njegovim tau-vezujućim fragmentom prema bilo kojem od zahtjeva 1-3, imunohistokemijom (IHC), i
(b) uspoređivanje razine modificiranog ili agregiranog tau-a s referentnim standardom koji pokazuje razinu patološki modificiranog ili agregiranog tau-a u jednom ili više kontrolnih subjekata,
pri čemu je razlika ili sličnost između nivoa patološki modificiranog ili agregiranog tau-a i norma referentne vrijednosti pokazuje da ljudski subjekt ima neurodegenerativnu taupatiju.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745410P | 2012-12-21 | 2012-12-21 | |
PCT/US2013/076952 WO2014100600A2 (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
EP13818637.4A EP2935326B1 (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201422T1 true HRP20201422T1 (hr) | 2021-02-19 |
Family
ID=49920689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201422TT HRP20201422T1 (hr) | 2012-12-21 | 2020-09-07 | Ljudska anti-tau antitijela |
Country Status (26)
Country | Link |
---|---|
US (4) | US9598484B2 (hr) |
EP (2) | EP2935326B1 (hr) |
JP (1) | JP6284548B2 (hr) |
KR (1) | KR102234324B1 (hr) |
CN (2) | CN111205368B (hr) |
AU (1) | AU2013361107B2 (hr) |
BR (1) | BR112015014751A8 (hr) |
CA (1) | CA2896066C (hr) |
CY (1) | CY1123518T1 (hr) |
DK (1) | DK2935326T3 (hr) |
EA (1) | EA035932B1 (hr) |
ES (1) | ES2816700T3 (hr) |
HK (1) | HK1216538A1 (hr) |
HR (1) | HRP20201422T1 (hr) |
HU (1) | HUE051320T2 (hr) |
IL (1) | IL239556B (hr) |
LT (1) | LT2935326T (hr) |
MX (1) | MX2015008024A (hr) |
MY (1) | MY184251A (hr) |
PH (2) | PH12015501420B1 (hr) |
PT (1) | PT2935326T (hr) |
RS (1) | RS60899B1 (hr) |
SG (2) | SG10201705104UA (hr) |
SI (1) | SI2935326T1 (hr) |
WO (1) | WO2014100600A2 (hr) |
ZA (1) | ZA201504898B (hr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG189174A1 (en) | 2010-10-11 | 2013-05-31 | Biogen Idec Internat Neuroscience Gmbh | Human anti-tau antibodies |
KR102494798B1 (ko) | 2012-07-03 | 2023-02-06 | 워싱턴 유니버시티 | Tau에 대한 항체 |
MX2015012225A (es) | 2013-03-13 | 2016-01-08 | Prothena Biosciences Ltd | Inmunoterapia tau. |
US10301379B2 (en) * | 2014-06-26 | 2019-05-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
DE102014013571A1 (de) | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoklonaler Antikörper gegen humanes TAU-Protein |
ES2848376T3 (es) | 2014-11-19 | 2021-08-09 | Axon Neuroscience Se | Anticuerpos de tau humanizados en la enfermedad de Alzheimer |
CA2977648C (en) | 2015-02-24 | 2024-01-02 | Rpeptide, Llc | Anti-tau antibodies |
JO3576B1 (ar) * | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
SG10201911349YA (en) | 2015-06-05 | 2020-01-30 | Genentech Inc | Anti-tau antibodies and methods of use |
MA41669A1 (fr) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Anticorps se liant a tau |
KR20180025962A (ko) | 2015-07-06 | 2018-03-09 | 유씨비 바이오파마 에스피알엘 | 타우 결합 항체 |
MA43723A (fr) | 2016-03-14 | 2021-05-19 | Biogen Int Neuroscience Gmbh | Essai employant la phagocytose à médiation cellulaire initié par anticorps pour mesurer des protéines agrégées |
PL3452507T3 (pl) | 2016-05-02 | 2023-01-09 | Prothena Biosciences Limited | Immunoterapia tau |
SG11201808434WA (en) * | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
WO2017191561A1 (en) * | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
KR20230165883A (ko) | 2016-06-07 | 2023-12-05 | 바이오겐 인터내셔널 뉴로사이언스 게엠베하 | 알츠하이머병의 치료 방법 |
EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
JP6949102B2 (ja) | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
MX2019006330A (es) * | 2016-12-07 | 2019-09-26 | Genentech Inc | Anticuerpos anti-tau y metodos de uso. |
WO2018106781A1 (en) * | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
EP3583123A1 (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
CA3055866A1 (en) * | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Methods for detection of tau protein aggregation modulating compounds |
WO2018183175A1 (en) | 2017-03-28 | 2018-10-04 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
MX2019013045A (es) * | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
TWI809562B (zh) | 2017-10-16 | 2023-07-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
WO2019133799A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Florida Research Foundation | Monoclonal antibodies targeting microtubule-binding domain of tau protein |
CA3093198A1 (en) * | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
EP3774889A4 (en) * | 2018-03-11 | 2021-12-08 | Koorosh Shahpasand | CONFORMITY INDEPENDENT ANTIBODIES AGAINST NEUROTOXIC TAU PROTEINS |
CN112543648A (zh) | 2018-07-31 | 2021-03-23 | 伊莱利利公司 | 组合疗法 |
CA3111907A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
CA3117409A1 (en) | 2018-10-29 | 2020-05-07 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
JOP20210098A1 (ar) * | 2018-11-08 | 2023-01-30 | Prothena Biosciences Ltd | أجسام مضادة تتعرف على تاو |
WO2020252394A2 (en) * | 2019-06-13 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia |
US20230287107A1 (en) * | 2019-07-23 | 2023-09-14 | Shanghaitech University | Asic1 channel antagonist antibody |
TWI832183B (zh) | 2019-08-06 | 2024-02-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
WO2021079868A1 (ja) | 2019-10-25 | 2021-04-29 | 東洋紡株式会社 | レーザー印字可能なフィルムおよびそれを用いた包装体 |
MX2022016322A (es) | 2020-06-25 | 2023-01-24 | Merck Sharp & Dohme Llc | Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413. |
GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
TW202239765A (zh) * | 2020-12-16 | 2022-10-16 | 美商航海家醫療公司 | Tau結合化合物 |
KR20240049296A (ko) | 2021-08-27 | 2024-04-16 | 제넨테크, 인크. | 타우 병증을 치료하는 방법 |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
JP3319594B2 (ja) | 1990-03-20 | 2002-09-03 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体 |
ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
WO1993008302A1 (en) | 1991-10-25 | 1993-04-29 | Itt Automotive Europe Gmbh | Monoclonal antibodies directed against the microtubule-associated protein tau |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
PT669986E (pt) | 1992-11-13 | 2003-08-29 | Idec Pharma Corp | Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
ATE165866T1 (de) | 1992-12-14 | 1998-05-15 | Innogenetics Nv | Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung |
DE69434811T2 (de) | 1993-12-21 | 2007-03-01 | Innogenetics N.V. | Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen |
ATE234324T1 (de) | 1994-07-29 | 2003-03-15 | Innogenetics Nv | Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung |
AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
PL191251B1 (pl) | 1997-03-14 | 2006-04-28 | Idec Pharma Corp | Sposób wprowadzania żądanego DNA w docelowe miejsce w genomie ssaka i układ wektorów |
AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
JP4368196B2 (ja) | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
CN1494553A (zh) | 2001-01-29 | 2004-05-05 | IDECҩ�﹫˾ | 改变的抗体及其使用方法 |
AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
WO2003014960A2 (en) | 2001-08-03 | 2003-02-20 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
WO2003017918A2 (en) | 2001-08-24 | 2003-03-06 | Universität Zürich | A method of inducing the formation of neurofibrillary tangles in transgenic animals |
US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
ES2352668T3 (es) | 2002-08-14 | 2011-02-22 | Mitsubishi Chemical Medience Corporation | Anticuerpo específico para una proteína tau del sistema nervioso central. |
WO2004095031A1 (en) | 2003-04-24 | 2004-11-04 | Universität Zürich | Method of monitoring immunotherapy |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
US7083854B1 (en) | 2005-05-10 | 2006-08-01 | Cornell Research Foundation, Inc. | Fibers from polymer nanoclay nanocomposites by electrospinning |
CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
LT2436696T (lt) | 2007-01-05 | 2017-08-25 | University Of Zurich | Anti-beta-amiloido antikūnas ir jo panaudojimas |
KR101634719B1 (ko) * | 2008-04-25 | 2016-06-29 | 다이액스 코포레이션 | Fcrn에 대한 항체 및 이들의 용도 |
CN101307108B (zh) * | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
EP2440234A4 (en) * | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
KR101988672B1 (ko) | 2010-10-07 | 2019-06-12 | 에이씨 이뮨 에스.에이. | 타우를 인식하는 포스포특이적 항체 |
SG189174A1 (en) * | 2010-10-11 | 2013-05-31 | Biogen Idec Internat Neuroscience Gmbh | Human anti-tau antibodies |
CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
US8697076B2 (en) | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
-
2013
- 2013-12-20 SG SG10201705104UA patent/SG10201705104UA/en unknown
- 2013-12-20 EP EP13818637.4A patent/EP2935326B1/en active Active
- 2013-12-20 CA CA2896066A patent/CA2896066C/en active Active
- 2013-12-20 EP EP20178431.1A patent/EP3792278A3/en not_active Withdrawn
- 2013-12-20 MX MX2015008024A patent/MX2015008024A/es active IP Right Grant
- 2013-12-20 SI SI201331780T patent/SI2935326T1/sl unknown
- 2013-12-20 MY MYPI2015001581A patent/MY184251A/en unknown
- 2013-12-20 EA EA201591020A patent/EA035932B1/ru unknown
- 2013-12-20 US US14/654,176 patent/US9598484B2/en active Active
- 2013-12-20 PT PT138186374T patent/PT2935326T/pt unknown
- 2013-12-20 DK DK13818637.4T patent/DK2935326T3/da active
- 2013-12-20 RS RS20201060A patent/RS60899B1/sr unknown
- 2013-12-20 LT LTEP13818637.4T patent/LT2935326T/lt unknown
- 2013-12-20 KR KR1020157019330A patent/KR102234324B1/ko active IP Right Grant
- 2013-12-20 ES ES13818637T patent/ES2816700T3/es active Active
- 2013-12-20 AU AU2013361107A patent/AU2013361107B2/en active Active
- 2013-12-20 BR BR112015014751A patent/BR112015014751A8/pt not_active Application Discontinuation
- 2013-12-20 CN CN201911004609.5A patent/CN111205368B/zh active Active
- 2013-12-20 WO PCT/US2013/076952 patent/WO2014100600A2/en active Application Filing
- 2013-12-20 JP JP2015549784A patent/JP6284548B2/ja active Active
- 2013-12-20 SG SG11201504822VA patent/SG11201504822VA/en unknown
- 2013-12-20 HU HUE13818637A patent/HUE051320T2/hu unknown
- 2013-12-20 CN CN201380073531.7A patent/CN105324394B/zh active Active
-
2015
- 2015-06-19 PH PH12015501420A patent/PH12015501420B1/en unknown
- 2015-06-21 IL IL239556A patent/IL239556B/en active IP Right Grant
- 2015-07-08 ZA ZA201504898A patent/ZA201504898B/en unknown
-
2016
- 2016-04-19 HK HK16104461.4A patent/HK1216538A1/zh unknown
-
2017
- 2017-02-08 US US15/427,843 patent/US20170369560A1/en not_active Abandoned
-
2018
- 2018-06-27 US US16/020,346 patent/US20190169274A1/en not_active Abandoned
-
2019
- 2019-09-24 US US16/580,152 patent/US20200262895A1/en not_active Abandoned
-
2020
- 2020-09-07 HR HRP20201422TT patent/HRP20201422T1/hr unknown
- 2020-09-09 CY CY20201100854T patent/CY1123518T1/el unknown
-
2021
- 2021-01-13 PH PH12021550083A patent/PH12021550083A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201422T1 (hr) | Ljudska anti-tau antitijela | |
JP2014503178A5 (hr) | ||
JP2017205118A5 (hr) | ||
IL310464A (en) | Anti-PHF-tau antibodies and uses thereof | |
IL225568A (en) | Phospho-specific antibodies for tau detection | |
JP2016029056A5 (hr) | ||
HRP20150831T1 (hr) | Humana anti-alfa- sinuklein auto-protutijela | |
JP2016503065A5 (hr) | ||
HRP20171190T1 (hr) | Protutijelo protiv beta-amiloida i njegove upotrebe | |
JP2016511254A5 (hr) | ||
Zhang et al. | Ultrasensitive and selective detection of Staphylococcus aureus using a novel IgY-based colorimetric platform | |
JP2015505665A5 (hr) | ||
JP2008533986A5 (hr) | ||
JP2016516997A5 (hr) | ||
JP2015531768A5 (hr) | ||
JP2014528695A5 (hr) | ||
EP3435085A1 (en) | Composition and kit for diagnosing behavioral addiction, and method of detecting presenilin-1 for diagnosis of behavioral addiction using the same | |
JP2015527365A5 (hr) | ||
JP2017522886A5 (hr) | ||
JP2015527368A5 (hr) | ||
RU2016144178A (ru) | Антитело против muc1 или его антигенсвязывающий фрагмент и его применение | |
Zhu et al. | Combining magnetic nanoparticle with biotinylated nanobodies for rapid and sensitive detection of influenza H3N2 | |
Trilling et al. | A broad set of different llama antibodies specific for a 16 kDa heat shock protein of Mycobacterium tuberculosis | |
Marco | Molecular methods for septicemia diagnosis | |
JP2018534236A5 (hr) |